Doxorubicin (DOX) is an anthracycline drug used to treat many cancer diseases. Similarly to other cytostatic drugs, DOX has serious side effects; the biggest obstacle is the cardiotoxicity. With the aim of lowering the negative side effects and to target the DOX into the tumor tissue, the different nanoparticles (NPs) are studied. The aim of this work was to synthetized different NPs and conjugated them with DOX and determine the binding capacity of the NPs. For this experiment, carbon nanotubes (CNTs), graphene oxide (GO), fullerene (FUL) and liposomes (LIP) were used. The highest binding capacity was observed in GO (85%). Subsequently the toxicity of NPs and NPs-DOX conjugates was analyzed in in vivo system (chicken embryos). Some NPs (GO) can increase the toxicity of DOX, whereas other NPs (LIP, CNTs) decrease DOX toxicity.
[1] Chen, Y. et al. Anticancer efficacy enhancement and attenuation of side
effects of doxorubicin with titanium dioxide nanoparticles. International
Journal of Nanomedicine, 2011, vol. 6, pp. 2321-2326. ISSN 1178-
2013.
[2] Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy.
Nature Nanotechnology, 2007, vol. 2, no. 12, pp. 751-760. ISSN 1748-
3387.
[3] Du, J. Z. et al. Tailor-Made Dual pH-Sensitive Polymer-Doxorubicin
Nanoparticles for Efficient Anticancer Drug Delivery. Journal of the
American Chemical Society, 2011, vol. 133, no. 44, pp. 17560-17563.
ISSN 0002-7863.
[4] li, Y. L. et al. Reversibly Stabilized Multifunctional Dextran
Nanoparticles Efficiently Deliver Doxorubicin into the Nuclei of Cancer
Cells. Angewandte Chemie-International Edition, 2009, vol. 48, no. 52,
pp. 9914-9918. ISSN 1433-7851.
[5] Brigger, I. et al. Nanoparticles in cancer therapy and diagnosis.
Advanced Drug Delivery Reviews, 2012, vol. 64, pp. 24-36. ISSN 0169-
409X.
[6] Malam, Y. et al. Current Trends in the Application of Nanoparticles in
Drug Delivery. Current Medicinal Chemistry, 2011, vol. 18, no. 7, pp.
1067-1078. ISSN 0929-8673.
[7] Ayen, W. Y. a KUMAR, N. In vivo Evaluation of Doxorubicin-Loaded
(PEG)(3)-PLA Nanopolymersomes (PolyDoxSome) Using DMBAInduced
Mammary Carcinoma Rat Model and Comparison with
Marketed LipoDox (TM). Pharmaceutical Research, 2012, vol. 29, no.
9, pp. 2522-2533. ISSN 0724-8741.
[8] Chen, Y.-C. et al. Non-metallic nanomaterials in cancer theranostics: a
review of silica- and carbon-based drug delivery systems. Science and
Technology of Advanced Materials, 2013, vol. 14, no. 4. ISSN 1468-
6996.
[9] Lim, D. J. et al. Carbon-based drug delivery carriers for cancer therapy.
Archives of Pharmacal Research, 2014, vol. 37, no. 1, pp. 43-52. ISSN
0253-6269.
[10] Ali-Boucetta, H. et al. Multiwalled carbon nanotube-doxorubicin
supramolecular complexes for cancer therapeutics. Chemical
Communications, 2008, no. 4, pp. 459-461. ISSN 1359-7345.
[11] Novoselov, K. S. et al. A roadmap for graphene. Nature, 2012, vol. 490,
no. 7419, pp. 192-200. ISSN 0028-0836.
[12] Huang, X. et al. Graphene-based composites. Chemical Society Reviews,
2012, vol. 41, no. 2, pp. 666-686. ISSN 0306-0012.
[13] Dellinger, A. et al. Application of fullerenes in nanomedicine: an update.
Nanomedicine, 2013, vol. 8, no. 7, pp. 1191-1208. ISSN 1743-5889.
[14] Chen, Z. et al. Applications of functionalized fullerenes in tumor
theranostics. Theranostics, 2012, vol. 2, no. 3, pp. 238-250. ISSN 1838-
7640.
[15] Swenson, C. E. et al. Liposome technology and the development of
Myocet (TM) (liposomal doxorubicin citrate). Breast, 2001, vol. 10, pp.
1-7. ISSN 0960-9776.
[16] Barenholz, Y. a Peer, D. Liposomes and other assemblies as drugs and
nano-drugs: From basic and translational research to the clinics preface.
Journal of Controlled Release, 2012, vol. 160, no. 2, pp. 115-116. ISSN
0168-3659.
[17] Lowery, A. et al. Tumor-targeted delivery of liposome-encapsulated
doxorubicin by use of a peptide that selectively binds to irradiated
tumors. Journal of Controlled Release, 2011, vol. 150, no. 1, pp. 117-
124. ISSN 0168-3659.
[18] Batist, G. et al. Reduced cardiotoxicity and preserved antitumor efficacy
of liposome-encapsulated doxorubicin and cyclophosphamide compared
with conventional doxorubicin and cyclophosphamide in a randomized,
multicenter trial of metastatic breast cancer. Journal of Clinical
Oncology, 2001, vol. 19, no. 5, pp. 1444-1454. ISSN 0732-183X.
[19] Gyoengyoesi, M. et al. Comparison of the cardiotoxic effect of
doxorubicin and liposome-encapsulation of doxorubicin under
experimental condition. Annals of Oncology, 2014, vol. 25. ISSN 0923-
7534.
[20] Hummers, W. S. a Offeman, R. E. Preparation of Graphitic Oxide.
Journal of the American Chemical Society, 1958, vol. 80, no. 6, pp.
1339-1339. ISSN 0002-7863.
[21] Blazkova, I. et al. Study of fluorescence of doxorubicin in muscle tissue
using highly sensitive fluorescence sensing. Chem. Sensors, 2014, vol. 4,
no. 9, pp. 1-6. ISSN 2231-6035.
[22] Kensova, R. et al. The Effect of Cadmium Ions and Cadmium
Nanoparticles on Chicken Embryos and Evaluation of Organ
Accumulation. International Journal of Electrochemical Science, 2015,
vol. 10, no. 4, pp. 3623-3634. ISSN 1452-3981.
[23] Konecna, R. et al. Doxorubicin encapsulation investigated by capillary
electrophoresis with laser-induced fluorescence detection.
Chromatographia, 2014, vol. 77, no. 21-22, pp. 1469-1476. ISSN 0009-
5893.
[24] Kominkova, M. et al. Study of functional qualities of different types of
tailored liposomes with encapsulated doxorubicin using electrochemical
and optical methods. International Journal of Electrochemical Science,
2014, vol. 9, no. 6, pp. 2993-3007. ISSN 1452-3981.
[25] Blazkova, I. et al. Apoferritin modified magnetic particles as
doxorubicin carriers for anticancer drug delivery. Int. J. Mol. Sci., 2013,
vol. 14, no. 7, pp. 13391-13402. ISSN 1422-0067.
[26] Blazkova, I. et al. Fullerene as a transporter for doxorubicin investigated
by analytical methods and in vivo imaging. Electrophoresis, 2014, vol.
35, no. 7, pp. 1040-1049. ISSN 0173-0835.
[27] Patel, K. J. et al. Distribution of the anticancer drugs doxorubicin,
mitoxantrone and topotecan in tumors and normal tissues. Cancer
Chemotherapy and Pharmacology, 2013, vol. 72, no. 1, pp. 127-138.
ISSN 0344-5704.
[28] Bouccara, S. et al. Enhancing fluorescence in vivo imaging using
inorganic nanoprobes. Current Opinion in Biotechnology, 2015, vol. 34,
pp. 65-72. ISSN 0958-1669.
[1] Chen, Y. et al. Anticancer efficacy enhancement and attenuation of side
effects of doxorubicin with titanium dioxide nanoparticles. International
Journal of Nanomedicine, 2011, vol. 6, pp. 2321-2326. ISSN 1178-
2013.
[2] Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy.
Nature Nanotechnology, 2007, vol. 2, no. 12, pp. 751-760. ISSN 1748-
3387.
[3] Du, J. Z. et al. Tailor-Made Dual pH-Sensitive Polymer-Doxorubicin
Nanoparticles for Efficient Anticancer Drug Delivery. Journal of the
American Chemical Society, 2011, vol. 133, no. 44, pp. 17560-17563.
ISSN 0002-7863.
[4] li, Y. L. et al. Reversibly Stabilized Multifunctional Dextran
Nanoparticles Efficiently Deliver Doxorubicin into the Nuclei of Cancer
Cells. Angewandte Chemie-International Edition, 2009, vol. 48, no. 52,
pp. 9914-9918. ISSN 1433-7851.
[5] Brigger, I. et al. Nanoparticles in cancer therapy and diagnosis.
Advanced Drug Delivery Reviews, 2012, vol. 64, pp. 24-36. ISSN 0169-
409X.
[6] Malam, Y. et al. Current Trends in the Application of Nanoparticles in
Drug Delivery. Current Medicinal Chemistry, 2011, vol. 18, no. 7, pp.
1067-1078. ISSN 0929-8673.
[7] Ayen, W. Y. a KUMAR, N. In vivo Evaluation of Doxorubicin-Loaded
(PEG)(3)-PLA Nanopolymersomes (PolyDoxSome) Using DMBAInduced
Mammary Carcinoma Rat Model and Comparison with
Marketed LipoDox (TM). Pharmaceutical Research, 2012, vol. 29, no.
9, pp. 2522-2533. ISSN 0724-8741.
[8] Chen, Y.-C. et al. Non-metallic nanomaterials in cancer theranostics: a
review of silica- and carbon-based drug delivery systems. Science and
Technology of Advanced Materials, 2013, vol. 14, no. 4. ISSN 1468-
6996.
[9] Lim, D. J. et al. Carbon-based drug delivery carriers for cancer therapy.
Archives of Pharmacal Research, 2014, vol. 37, no. 1, pp. 43-52. ISSN
0253-6269.
[10] Ali-Boucetta, H. et al. Multiwalled carbon nanotube-doxorubicin
supramolecular complexes for cancer therapeutics. Chemical
Communications, 2008, no. 4, pp. 459-461. ISSN 1359-7345.
[11] Novoselov, K. S. et al. A roadmap for graphene. Nature, 2012, vol. 490,
no. 7419, pp. 192-200. ISSN 0028-0836.
[12] Huang, X. et al. Graphene-based composites. Chemical Society Reviews,
2012, vol. 41, no. 2, pp. 666-686. ISSN 0306-0012.
[13] Dellinger, A. et al. Application of fullerenes in nanomedicine: an update.
Nanomedicine, 2013, vol. 8, no. 7, pp. 1191-1208. ISSN 1743-5889.
[14] Chen, Z. et al. Applications of functionalized fullerenes in tumor
theranostics. Theranostics, 2012, vol. 2, no. 3, pp. 238-250. ISSN 1838-
7640.
[15] Swenson, C. E. et al. Liposome technology and the development of
Myocet (TM) (liposomal doxorubicin citrate). Breast, 2001, vol. 10, pp.
1-7. ISSN 0960-9776.
[16] Barenholz, Y. a Peer, D. Liposomes and other assemblies as drugs and
nano-drugs: From basic and translational research to the clinics preface.
Journal of Controlled Release, 2012, vol. 160, no. 2, pp. 115-116. ISSN
0168-3659.
[17] Lowery, A. et al. Tumor-targeted delivery of liposome-encapsulated
doxorubicin by use of a peptide that selectively binds to irradiated
tumors. Journal of Controlled Release, 2011, vol. 150, no. 1, pp. 117-
124. ISSN 0168-3659.
[18] Batist, G. et al. Reduced cardiotoxicity and preserved antitumor efficacy
of liposome-encapsulated doxorubicin and cyclophosphamide compared
with conventional doxorubicin and cyclophosphamide in a randomized,
multicenter trial of metastatic breast cancer. Journal of Clinical
Oncology, 2001, vol. 19, no. 5, pp. 1444-1454. ISSN 0732-183X.
[19] Gyoengyoesi, M. et al. Comparison of the cardiotoxic effect of
doxorubicin and liposome-encapsulation of doxorubicin under
experimental condition. Annals of Oncology, 2014, vol. 25. ISSN 0923-
7534.
[20] Hummers, W. S. a Offeman, R. E. Preparation of Graphitic Oxide.
Journal of the American Chemical Society, 1958, vol. 80, no. 6, pp.
1339-1339. ISSN 0002-7863.
[21] Blazkova, I. et al. Study of fluorescence of doxorubicin in muscle tissue
using highly sensitive fluorescence sensing. Chem. Sensors, 2014, vol. 4,
no. 9, pp. 1-6. ISSN 2231-6035.
[22] Kensova, R. et al. The Effect of Cadmium Ions and Cadmium
Nanoparticles on Chicken Embryos and Evaluation of Organ
Accumulation. International Journal of Electrochemical Science, 2015,
vol. 10, no. 4, pp. 3623-3634. ISSN 1452-3981.
[23] Konecna, R. et al. Doxorubicin encapsulation investigated by capillary
electrophoresis with laser-induced fluorescence detection.
Chromatographia, 2014, vol. 77, no. 21-22, pp. 1469-1476. ISSN 0009-
5893.
[24] Kominkova, M. et al. Study of functional qualities of different types of
tailored liposomes with encapsulated doxorubicin using electrochemical
and optical methods. International Journal of Electrochemical Science,
2014, vol. 9, no. 6, pp. 2993-3007. ISSN 1452-3981.
[25] Blazkova, I. et al. Apoferritin modified magnetic particles as
doxorubicin carriers for anticancer drug delivery. Int. J. Mol. Sci., 2013,
vol. 14, no. 7, pp. 13391-13402. ISSN 1422-0067.
[26] Blazkova, I. et al. Fullerene as a transporter for doxorubicin investigated
by analytical methods and in vivo imaging. Electrophoresis, 2014, vol.
35, no. 7, pp. 1040-1049. ISSN 0173-0835.
[27] Patel, K. J. et al. Distribution of the anticancer drugs doxorubicin,
mitoxantrone and topotecan in tumors and normal tissues. Cancer
Chemotherapy and Pharmacology, 2013, vol. 72, no. 1, pp. 127-138.
ISSN 0344-5704.
[28] Bouccara, S. et al. Enhancing fluorescence in vivo imaging using
inorganic nanoprobes. Current Opinion in Biotechnology, 2015, vol. 34,
pp. 65-72. ISSN 0958-1669.
@article{"International Journal of Chemical, Materials and Biomolecular Sciences:70255", author = "I. Blazkova and A. Moulick and V. Milosavljevic and P. Kopel and M. Vaculovicova and V. Adam and R. Kizek", title = "The Toxicity of Doxorubicin with Nanotransporters", abstract = "Doxorubicin (DOX) is an anthracycline drug used to treat many cancer diseases. Similarly to other cytostatic drugs, DOX has serious side effects; the biggest obstacle is the cardiotoxicity. With the aim of lowering the negative side effects and to target the DOX into the tumor tissue, the different nanoparticles (NPs) are studied. The aim of this work was to synthetized different NPs and conjugated them with DOX and determine the binding capacity of the NPs. For this experiment, carbon nanotubes (CNTs), graphene oxide (GO), fullerene (FUL) and liposomes (LIP) were used. The highest binding capacity was observed in GO (85%). Subsequently the toxicity of NPs and NPs-DOX conjugates was analyzed in in vivo system (chicken embryos). Some NPs (GO) can increase the toxicity of DOX, whereas other NPs (LIP, CNTs) decrease DOX toxicity.
", keywords = "Chicken embryos, Doxorubicin, Nanotransporters,
Toxicity
", volume = "9", number = "7", pages = "813-4", }
